<< Back To Search

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients with Relapsed/Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation you are interested in this trial
NCT05896228
Age 18 - 75
Sex Both
Phase Phase 2
Third Opinion Trial Synopsis
In this clinical study, researchers are exploring a new treatment approach for patients with a specific type of blood cancer. The study focuses on using a combination of therapies to improve patient outcomes. Here are some key details about the study:
  • The treatment involves a unique combination of medications that have not been widely used together before.
  • Patients will receive the treatment in a controlled environment, allowing researchers to closely monitor its effects.
  • The study aims to assess how well this combination works compared to standard treatments.
  • Participants will be closely observed for any side effects and overall health improvements.
  • This study is designed to gather data that could lead to new treatment options for patients who may not respond well to existing therapies.
Overall, this study is significant because it seeks to provide new hope for patients by testing a novel approach that could potentially enhance treatment effectiveness and improve quality of life.
Third Opinion AI Generated Synopsis

Trial Summary
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.
from ClinicalTrials.gov

Locations & Contact

Fill out the form and to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Please share any additional considerations or concerns:
Example: Are you newly diagnosed? What treatments have you already been on?

Contacts: